Linnaeus Therapeutics, Inc. announced the issuance of EP patent 3823617 by the European Patent Office (EPO) covering the pharmaceutical composition of matter for their lead compound, LNS8801.
LNS8801 modulates G protein-coupled estrogen receptor activity, and has the potential to offer therapeutic benefits for diseases and conditions mediated through these receptors.
Linnaeus is currently conducting a phase 1/2 study for advanced cancer treatment and based on promising results from this study, it plans to initiate a pivotal trial in patients with metastatic cutaneous melanoma who have had confirmed progression on immune checkpoint inhibitors.
Read more about the company and its patent here.